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nloaded fromHeat shock proteins (HSPs) are stress-induced chaperones that are involved in neurological disease. Although
increasingly implicated in behavioral disorders, the mechanisms of HSP action, and the relevant functional path-
ways, are still unclear. We examined whether oral administration of geranylgeranylacetone (GGA), a known HSP
inducer, produced an antidepressant effect in a social defeat stress model of depression in mice. We also in-
vestigated the possible molecular mechanisms involved, particularly focusing on hippocampal neurogenesis
and neurotrophic factor expression. In stressed mice, hippocampal HSP105 expression decreased. However,
administration of GGA increased HSP105 expression and improved depression-like behavior, induced hippo-
campal cell proliferation, and elevated brain-derived neurotrophic factor (BDNF) levels in mouse hippocampus.
Co-treatment with GGA and the BDNF receptor inhibitor K252a suppressed the antidepressant effects of GGA.
HSP105 knockdown decreased BDNF mRNA levels in HT22 hippocampal cell lines and hippocampal tissue and
inhibited the GGA-mediated antidepressant effect. These observations suggest that GGA administration is a






Heat shock proteins (HSPs), which act as molecular chaperones, play
an important regulatory role for the maintenance of cellular ho-
meostasis (1, 2). HSPs are subdivided into distinct families based on
their molecular weight and sequence homology: HSP110, HSP90,
HSP70, HSP60, HSP40, and low–molecular weight HSPs. Each HSP
family has specific functions that have been the subject of different re-
views (3, 4). There is increasing evidence thatHSPs are associated with
neuronal protection. HSP70 and HSP40 abrogate polyglutamine tox-
icity by refolding and solubilizing pathogenic proteins (5–7). HSP70
also regulates the activity of glucocorticoid receptors, which play an
important role in depression (8). Localization studies have shown a
wide distribution of HSP110 in the cerebral cortex, hippocampus, thal-
amus, and hypothalamus (9). HSP90 is preferentially expressed in the
nonstressed mammalian brain (10). In environmentally stressed mice,
the expression of HSP90, HSP70, and HSP105 (a member of HSP110)
in the hippocampus is altered (11). Thus, a huge body of evidence has
accumulated, suggesting that the activities of HSPs are associated with
various behavioral disorders. These reports allow us to hypothesize
that HSPs are a new therapeutic target for psychological disorders,
including depression.
Geranylgeranylacetone (GGA) is an acyclic isoprenoid compound,
which has been widely used as an anti-ulcer agent. GGA has been re-
ported to induceHSP synthesis in various tissues, including the gastric
mucosa, liver, and central nervous system (12–14). Oral administra-
tion of GGA induces HSP70 expression in the rat brain and plays
an important role in ischemic brain injury (14, 15). However, it isstill unclear whether GGA is associated with the improvement of
depression-like behavior.
The psychopathology of depression is multifaceted and is known to
be accompanied by a decrease or impairment in neurogenesis in
the hippocampus (16, 17). The relationship between HSPs and hippo-
campal neurogenesis has been reported. HSPB8 has been shown to be
neuroprotective in the mouse adult hippocampus (18). Furthermore,
HSP27 (HSP25 is the mouse homolog of the human HSP27) is neuro-
protective against the harmful effects of ethanol administration in the
mouse brain (19). However, the effect of GGA administration on hip-
pocampal neurogenesis in mice remains unclear. Here, we examined
whether oral GGA administration induced an antidepressant effect in
a social defeat stress model of depression in mice. We also investigated
the possible molecular mechanisms involved, particularly focusing on
hippocampal neurogenesis and neurotrophic factor expression. Fur-
thermore, we evaluated the association of teprenone (pharmaceutical
name of GGA) use and drug-induced depression using the U.S. Food
and Drug Administration (FDA) Adverse Event Reporting System
(FAERS), a large and useful database of adverse events.RESULTS
Effects of social defeat stress on HSP mRNA expression in
the mouse hippocampus
To examine the effects of social defeat stress on HSPs, we used quanti-
tative reverse transcription polymerase chain reaction (PCR) to detect
HSP25,HSP60,HSP72, andHSP105mRNA level changes in the hippo-
campus after stress exposure. To induce social defeat stress, we subjected
mice daily to 10-min defeat sessions, followed by continuous protected
sensory contact with their aggressor for a total of 15 days. Each day,
experimental mice were exposed to a new resident home cage.
HSP25, HSP60, and HSP72mRNA levels did not show any significant
differences between control and stressed mice. However, HSP105
mRNA levels were significantly decreased when compared to control
(t test, P = 0.0061; Fig. 1).1 of 12









Oral administration of GGA induces HSP expression in the
mouse hippocampus and rescues depression-like behavior
by increasing hippocampal cell maturation
Because we found decreasedHSP105mRNA expression in the hippo-
campus following stress exposure, we next determined whether
HSP105 activity plays a role in behavioral development. To demon-
strate whether or not GGA could increase hippocampal HSPs,
8-week-old mice received GGA [0.34% (w/v)] in their drinking water
for 15 days. Following GGA administration, we found significantly
increased HSP25 and HSP60 levels compared with vehicle-treated
mice (Fig. 2, A and B). Further,HSP72 levels were increased in stressed
mice and after GGA treatment (Fig. 2C). In contrast, HSP105 levels
were reduced in stressed mice but increased by GGA (Fig. 2D). In ad-
dition, wemeasuredHSP105 protein expression levels. GGAand stress
resulted in a significant interaction, with stress-reducing HSP105 pro-
tein in stressed mice only (Fig. 2E).
To investigate the effects of exogenously increasedHSPsondepression-
like behavior in stressed mice, we monitored social interaction time.
Stressed mice spent less time interacting with the unfamiliar CD1
mouse (Fig. 3A). This social avoidance is considered a measure of
depression-like behavior because it can be reversed by chronic, but
not acute, treatment with antidepressants (20). GGA treatment im-
proved defeatedmouse interaction time (Fig. 3A).We also examined
depression-like behavior using a forced swim test, tail suspension test,
and sucrose preference test. We found significantly increased im-
mobility time in the forced swim test after stress, which was decreased
by GGA (Fig. 3B). Similarly, immobility time in the tail suspension test
was significantly increased in stressedmice (Fig. 3C). Sucrose preference
displayed the same social interaction pattern, with stress decreasing and
GGA increasing sucrose preference (Fig. 3D). In contrast, total fluid
consumption was increased by stress (Fig. 3E). These results suggest
that GGA treatment induces antidepressant-like effects in stressed
mice. In addition, we also examined the general behavior of mice in
the open-field test. There were no differences in locomotor activity,
rearing activity, or time spent in the center area of the open-field test
(Fig. 3F).
Next, we analyzed granule neuron development using doublecortin
(DCX). Stressed mice had fewer DCX-positive cells in the subgranularHashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017zone of the dentate gyrus compared with nonstressed mice (Fig. 3G).
The number of DCX-positive cells in the granule cell layer of the den-
tate gyrus was significantly decreased in stressed mice. GGA adminis-
tration reduced the number of stress-induced DCX-positive cells. In
addition, we determined whether mature neuronal development is
altered in mouse brain sections immunostained with anti–neuronal
nuclei (NeuN), a widely used neuronal marker. However, we found
no differences in NeuN cells following stress or GGA treatment
(fig. S1). Thus, the social defeat stress model showed reduced neural
progenitor proliferation in the dentate gyrus, and GGA administration
rescued dentate gyrus maturation.
GGA-mediated HSP expression increases BDNF levels in
the hippocampus
We next determined if GGA-induced HSP expression improved
depression-like behavior by increasing hippocampal neural progenitor
proliferation. For this, we focused on neurotrophic factors in themouse
hippocampus. According to previous reports (21–24), the role of neu-
rotrophins, including brain-derived neurotrophic factor (BDNF), cil-
iary neurotrophic factor (CNTF), neurotrophin 3 (NT-3), and nerve
growth factor (NGF), in depression-like behavior has been well
studied. In the stressed with GGA treatment group, BDNF, but not
NGF, CNTF, or NT-3, mRNA expression was significantly higher
(Fig. 4, A to D). We also investigated BDNF protein expression by
Western blotting and immunohistochemistry and found a similar pat-
tern as for BDNF mRNA, with GGA increasing BDNF protein levels
(Fig. 4E and fig. S2).
The BDNF receptor inhibitor K252a suppresses GGA-induced
antidepressant-like effects
To further characterize the involvement of BDNF expression on the
GGA-mediated antidepressant effect, we inhibited BDNF activation
using a BDNF receptor inhibitor (K252a; 25 mg/kg per day) during
stress exposure in mice. Following GGA administration, the social in-
teraction rate significantly increased (Fig. 5A). In contrast, immobility
time was not significant in either the forced swim test or tail suspen-
sion test, but K252a inhibited the GGA-dependent antidepressant
effect (Fig. 5B, P = 0.059; Fig. 5C, P = 0.055). Further, sucrose prefer-
ence was elevated in stressed mice by GGA, but reduced by K252a,
with total intake unaffected (Fig. 5D). In contrast, K252a treatment
did not significantly affect general motor behavior in the open-field
test (locomotor activity, rearing activity, and time spent in the center
area) (Fig. 5E). We also determined whether combined K252a and
GGA influences nonstress mouse behavior. However, only total fluid
intake was significantly reduced by GGA (fig. S3).
HSP105-siRNA treatment suppresses the expression of BDNF
We have already shown that social defeat stress significantly decreases
HSP105 but not other HSPs. GGA administration increased HSPs and
BDNF and abolished stress-induced depression-like behavior. From
these results, we hypothesized that HSP105 plays a critical role in
the GGA-mediated antidepressant effect via BDNF elevation. To elu-
cidate the effects of HSP105 knockdown on BDNF expression in hip-
pocampus cells, we administered either HSP105–small interfering
RNA (siRNA) or nontargeting control siRNA in HT22 cells and ex-
posed them to 50 mM GGA at 41°C for 2 hours. A marked reduction
inHSP105mRNAwas observed inHT22 cells (one-way ANOVA, P <
0.05; Fig. 6A). At the same time, the siRNA decreased the level of
BDNF mRNA (one-way ANOVA, P < 0.05; Fig. 6B). Next, to moreFig. 1. Stress-induced HSP mRNA level changes in the hippocampus. Quan-
titative reverse transcription PCR analysis showing the expression levels of HSP25,
HSP60, HSP72, and HSP105 (n = 4 to 5 animals per group). Each bar indicates the
mean ± SEM. Statistically different groups are indicated by letters.2 of 12









Fig. 2. Effects of GGA on HSP expression in the hippocampus. The level of HSP mRNA in the hippocampus was detected by quantitative reverse transcription PCR.
HSP25 mRNA (A), HSP60 mRNA (B), HSP72 mRNA (C), HSP105 mRNA (D), and HSP105 protein (E) (n = 5 to 6 animals per group). Each bar indicates the mean ± SEM, with
significant differences as inserts on the chart (P < 0.05). Groups were first tested by two-way analysis of variance (ANOVA). Then, if a statistical interaction was observed
between factors, comparison of all four groups was performed by one-way ANOVA with Tukey’s post hoc test. Statistically different groups are indicated by letters. n.s.,
not significant; VEH, vehicle; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017 3 of 12









Fig. 3. GGA administration rescues depression-like behavior and hippocampal proliferation. (A) Interaction rate in the interaction test. (B) Immobility times in the
forced swim test. (C) Immobility times in the tail suspension test. Sucrose preferences (D) and total fluid intake (E) in the sucrose preference test. (F) General behavior in
the open-field test locomotor activity, rearing activity, or time spent in the center area (n = 4 to 5 animals per group). (G) Photomicrographs of the dentate gyrus
showing representative DCX-positive cells. Scale bar, 100 mm. Arrows show immunopositive cells. Right: Number of DCX-positive cells. Each bar indicates the mean ±
SEM, with significant differences shown as inserts on the chart (P < 0.05). Groups were first tested by two-way ANOVA. Then, if a statistical interaction was observed
between factors, comparison of all four groups was performed by one-way ANOVA with Tukey’s post hoc test. Statistically different groups are indicated by letters.Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017 4 of 12









specifically analyze the role of HSP105 on BDNF expression in vivo, we
injected HSP105-siRNA or nontargeting control into the mouse brain,
and after 24hours,HSP105protein expressionwas evaluatedbyWestern
blotting. HSP105-siRNA significantly decreased HSP105 levels by ~80%
in the mouse hippocampus compared with the nontargeting control
(Fig. 6C). We also investigated HSP25, HSP60, and HSP72 expression
in HSP105-siRNA mouse hippocampus but found no significant
changes in HSP expression (fig. S4). Next, we injected HSP105-siRNAHashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017into the mouse brain on days 1, 7, and 14 during a 15-day stress expo-
sure. We observed that the decreases seen in immobility time in the
forced swim test and tail suspension test following GGA treatment in
stressed mice were absent in HSP105-siRNA knockdown mice (one-
way ANOVA, P < 0.05; Fig. 6, D and E). Furthermore, the increase in
social interaction rate induced by GGA administration was absent in
HSP105-siRNA (one-way ANOVA, P < 0.05; Fig. 6F). In the sucrose
preference test, HSP105-siRNA did not further affect sucrose preferenceFig. 4. Effects of GGA administration on mRNA levels of neurotrophic factors in the stressed mouse hippocampus. Mice were administered vehicle or GGA orally.
Quantitative reverse transcription PCR analysis showing the expression levels of (A) BDNF, (B) NGF, (C) CNTF, and (D) NT-3 (n = 5 animals per group). (E) Western blotting
of BDNF protein expression in mouse hippocampus (n = 4 to 5 animals per group). Each bar indicates the mean ± SEM, with significant differences shown as inserts on
the chart (P < 0.05). Groups were first tested by two-way ANOVA. Then, if a statistical interaction was observed between factors, comparison of all four groups was
performed by one-way ANOVA with Tukey’s post hoc test. Statistically different groups are indicated by letters.5 of 12









and total fluid intake (Fig. 6G). Combining HSP105-siRNA and GGA
treatment significantly decreased BDNF levels in stressed mouse hippo-
campus (one-way ANOVA, P < 0.05; Fig. 6H).
FAERS database
The characteristics of the study population are presented in Table 1.
The number of cases, which claimed depressive events (major depres-
sion, agitated depression, or depression suicidal) during the study peri-
od, was 49,839. Among those, 15,353 reports were male and 34,486
reports were female. The mean age of cases was 48.3 years. In contrast,
the number of non-cases, which include events other than depression,
was 2,277,014. Among those, 856,772 reports were male and 1,420,242
reports were female. The mean age of non-cases was 54.1 years. The
data on teprenone (GGA)–associated depression are presented in Table 2.
It is well known that administration of peginterferon a-2a, peginterfer-Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017on a-2b, or ribavirin elicits depressive events (25, 26). Because of these
previous reports, we focused on drugs that cause drug-induced depres-
sion. The number of reports, where subjects were administered either
peginterferon a-2a, peginterferon a-2b, or ribavirin, but not teprenone
(GGA), and claimed depressive events was 1626 (males: 904; females:
722). Coadministration of teprenone (GGA) decreased the number of
reports, with the number of subjects administered peginterferon a-2a,
peginterferona-2b, or ribavirin and claiming depressive events being 10
(males, 5; females, 5). In contrast, the number of subjects administered
peginterferon a-2a, peginterferon a-2b, or ribavirin, but not teprenone
(GGA), and claiming other events unrelated to depression was 41,348
(males, 23,393; females, 17,955). Coadministration of teprenone
(GGA) decreased the number of reports to 403 (males, 196; females,
207). If no teprenone (GGA) was used, the reporting odds ratio (ROR)
for the use of peginterferon a-2a, peginterferon a-2b, or ribavirin wasFig. 5. The BDNF receptor inhibitor K252a suppresses GGA-induced antidepressant-like effects. (A) Social interaction rate in the interaction test. (B) Immobility times
in the forced swim test. (C) Immobility times in the tail suspension test. (D) Sucrose preference and total fluid intake in the sucrose preference test. (E) No significant effect on
general behavior, locomotor activity, rearing activity, or time spent in the center area in the open-field test (n = 5 animals per group). Each bar indicates themean ± SEM, with
significant differences shown as inserts on the chart (P < 0.05). Groups were first tested by two-way ANOVA. Then, if a statistical interaction was observed between factors,
comparison of all four groups was performed by one-way ANOVA with Tukey’s post hoc test. Statistically different groups are indicated by letters.6 of 12









Fig. 6. HSP105-siRNA in HT22 cells or stressed mouse brain decreased BDNF levels and abolished antidepressant effects. (A) Level ofHSP105mRNA in HT22 cells
(ANOVA, F2,13 = 544.1, n = 5 to 6). (B) Level of BDNFmRNA in HT22 cells (ANOVA, F2,13 = 10.74, n = 5 to 6). (C) The level of HSP105 protein in the hippocampus was detected
by Western blotting (n = 3). (D) Immobility times in the forced swim test (ANOVA, F2,11 = 6.03). (E) Immobility times in the tail suspension test (ANOVA, F2,11 = 15.02). (F) Social
interaction rate in the interaction test (ANOVA, F2,11 = 5.00). (G) Sucrose preference and total fluid intake in the sucrose preference test. (H) Level of BDNFmRNA and protein in the
mouse hippocampus (ANOVA, F2,11 = 4.54 and F2,12 = 5.41, respectively) (n = 4 to 5 animals per group). Each bar indicates the mean ± SEM. GGA + NTC, GGA with nontargeting
control; GGA + HSP105-siRNA, GGA with HSP105-siRNA treatment. Statistically different groups are indicated by letters.Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017 7 of 12









1.82 (95% CI, 1.73 to 1.91). If the users were administered teprenone
(GGA), the ROR for peginterferon a-2a, peginterferon a-2b, or riba-
virin was 1.13 (95% CI, 0.61 to 2.12), indicating that coadministration
with teprenone (GGA) suppressed drug-induced depression by inter-
feron.DISCUSSION
The present study shows that social defeat stress induces depression-like
behavior by decreasing HSP105 in the mouse hippocampus. Moreover,
we showed that theHSP inducerGGA can increaseHSP105 expression,
rescue mouse behavior, increase cell proliferation in the hippocampus,
and increase levels of BDNF. Inhibition of the BDNF receptor abolished
the GGA-mediated antidepressant effect. HSP105 knockdown also
inhibited the GGA-mediated antidepressant effect. Furthermore, the
FAERS database showed that combined treatment with GGA alleviated
drug-induced depression in patients. Together, these results elucidate a
novel function for GGA, suggesting that GGA-mediated HSP105 may
enhance BDNF levels to alleviate depression-like behavior.
GGA is centrally acting after oral administration and has been used
clinically for many years as a treatment for peptic ulcers without seri-
ous side effects (27). Yamagami et al. (13) have reported that GGA ad-Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017ministration augmented HSP72 expression in response to stress, but
this effect was induced with some stress condition. However, we show
here that GGA administration significantly increases HSPs and, in par-
ticular,HSP105mRNA inmouse hippocampus. It has been noted that
HSP110 is highly expressed in the brain in a similar manner to that
observed in heat-shocked cells (9). Furthermore, HSP105 expression
in naïve mouse hippocampal neurons was higher than in damaged
neurons (28). Thus, it is likely that HSP105 plays an important role
in the brain and that HSP105 may be sensitive to external influences
such as neuronal damage or GGA administration.
Althoughnumerous reports have shown thatGGAacceleratesHSP70
expression and plays an important role in brain injury, HSP105 has not
been thoroughly investigated (27, 29–31).HSP105belongs to theHSP110
family. HSP110 is distributed in the cerebral cortex, hippocampus,
thalamus, and hypothalamus (9). HSP105 inhibited stress-induced
apoptosis in PC12 neuronal cells (32). Recent evidence demonstrated
that chronic stress results in alterations to HSP105, with increased
levels of caspase-3 in the female mouse hippocampus (11). Thus,
HSP105 has been demonstrated to play a key role in neuroprotection.
Consistent with this, the present study demonstrated that HSP105 de-
creases in stressed mice and elicits depressive-like behavior. Further-
more, GGA-mediated HSP105-induced BDNF expression leads to
antidepressant effects against subsequent stressful situations. There
are three possibilities as to why HSP105 increases BDNF: (i) HSP105
may regulate enzymes that modulate the conversion of pro-BDNF to
BDNF; (ii) HSP105 may stabilize BDNF protein formation; and (iii)
HSP105 may activate BDNF transcription factors, such as adenosine
3′,5′-monophosphate response element–binding protein (CREB). In
general, if the level of transcription is increased, transcription factors
are activated. According to hypothesis (i) or (ii), BDNF protein expres-
sionwill increase regardless of BDNFmRNA levels. However, the pres-
ent study showed that BDNFmRNA levels were significantly increased
by GGA administration in the mouse hippocampus and HT22 cells.
These results suggest that HSP105 can directly or indirectly regulate
BDNF transcription factors. If HSP105 acts directly, HSP105may con-
trol transcription of BDNF via CREB, a key transcription factor for
BDNF induction (33). In contrast, if HSP105 acts indirectly, HSP105
may regulate factors that activate the transcription of BDNF, such as
mitogen-activated protein kinase (MAPK). Activation of the MAPK
pathway can also regulate transcription through phosphorylation of
CREB. Here, we observed that GGA treatment increased the mRNA
levels of BDNF but notNGF,NT-3, andCNTF. The genes that regulate
CREB are well known. However, detailed knowledge on which
transcription factors induce CNTF, NT-3, and NGF production is
lacking. Moreover, we also investigated phospho-CREB expression
in mouse hippocampus but found no significant changes between
stressed mice and GGA-stressed mice (fig. S5). It has been reported
that not only CREB but also CaRF (calcium-responsive transcription
factor), USF1/2 (upstream transcription factor 1/2), BHLHB2 (basic
helix-loop-helix B2 transcription factor), NFkB (nuclear factor kB),
and NFAT (nuclear factor of activated T cells) are related to BDNF
transcription (34). Therefore, our findings suggest that other
transcription factors are involved in the GGA-induced increase of
BDNF. Thus, identification of the transcription factors that regulate
the expression of neurotrophins is needed.
Neurotrophins bind to two classes of receptors, p75 and the tropo-
myosin receptor kinase (trk) receptors. The trkA receptor displays
high affinity for NGF, which induces the activation of the phosphati-
dylinositol 3-kinase (PI3K)–Akt pathway andMAPK pathway. BDNFTable 1. Characteristics of study population over 5 years (2010–2015)
in the FAERS database.Case with depression, n (%) Non-cases, n (%)Total 49,839 (100) 2,277,014 (100)Male 15,353 (30.8) 856,772 (37.6)Female 34,486 (69.2) 1,420,242 (62.4)Mean age (years) 48.3 54.1Table 2. Association of teprenone with depressive events in patient




ratio (95% CI)Total (male and female)Teprenone not present 1626 41,348 1.82 (1.73–1.92)Teprenone present 10 403 1.13 (0.61–2.12)MaleTeprenone not present 904 23,393 2.23 (2.08–2.39)Teprenone present 5 196 1.42 (0.59–3.46)FemaleTeprenone not present 722 17,955 1.67 (1.55–1.80)Teprenone present 5 207 0.99 (0.41–2.42)8 of 12









and NT-3 bind to trkB receptors and activate the MAPK pathway,
PI3K-Akt pathway, and phospholipase C–g–Ca2+ pathway. K252a in-
hibits the trk family of receptor tyrosine kinases and other serine/
threonine protein kinases (35). Here, we demonstrated that K252a
inhibited the GGA-mediated antidepressant effect. Furthermore,
GGA elicited an increase in HSP105, and an increase in BDNF, but
not NGF. These results support the hypothesis that GGA-mediated
HSP105 may modulate BDNF expression, which binds to trk recep-
tors to rescue depression-like behavior. To clarify whether HSP105
modulates BDNF expression, we performed HSP105 knockdown.
Here, we demonstrated for the first time thatHSP105 promotes BDNF
expression in the hippocampus, which results in the amelioration of
depression-like behavior. The effect of HSP105-siRNA was examined
inHT22 cells and themouse brain. In HT22 cells, HSP105 knockdown
significantly decreasedBDNFmRNAexpression. In addition,HSP105-
siRNA aggravated the GGA-mediated antidepressant effects in vivo.
Only the sucrose preference test showed no significant changes after
HSP105-siRNA treatment. Thus, we hypothesize thatHSP105may on-
ly have a slight effect in anhedonia-like behavior or, alternatively, that
the effect of HSP105 knockdownmay be insufficient to cause a change
in anhedonia behavior. In contrast, increased immobility time in the
tail suspension test was significantly inhibited by HSP105 knockdown.
These results suggest that the effects of HSP105 on hippocampal pro-
liferation and antidepressant effects are most likely mediated through
increases in BDNF expression. The decrease in hippocampal BDNF
levels is correlated with depression (21), and infusion of BDNF into
the hippocampus induces antidepressant effects in rodents (24).
GGA has always been considered a gastrointestinal drug for
protecting the mucosa. Here, we demonstrate that GGA reduced de-
pression-like behavior and BDNF expression in the stressed mouse
hippocampus. GGA can cross the blood-brain barrier (BBB), as indi-
cated here by the increase in HSP105 mRNA expression in the hippo-
campus following oral administration. This is further supported by
Mikuriya et al. (36), because GGA is a lipid-soluble agent that easily
crosses the BBB. In terms of drug dosage, 0.34% (w/v) GGA is a rather
high concentration compared with a clinical dose in humans (150 mg,
three times a day; approximately 1.5 to 3mg/kg) (37). Themedian lethal
dose (LD50) of GGA is more than 15,000 mg/kg by oral administration
in rodents (38). The dose chosen in this study was determined using
other reports that used GGA (800 mg/kg) for mice (31). Here, GGA
showed no adverse effects at a dose of 0.34% (w/v). Other reports also
showed that GGA had no adverse effects at high doses [800 mg/kg, or
0.25, 0.5, 1, and 2% (w/v)] in rodents (5, 31). In the FAERS database,
results suggested that the clinical dose in humans could help prevent the
onset of drug-induced depression. Here, we focused on medications
known to cause drug-induced depression. Peginterferon a-2a or pegin-
terferon a-2b is usually used for the treatment of chronic hepatitis
C. Ribavirin is also used as an antiviral drug for hepatitis C infection and
is often given in combination with peginterferon a-2a or peginterferon
a-2b. We observed that the reporting of depressive events decreased
when teprenone (GGA) was used in combination with peginterferon
or ribavirin. The ROR of peginterferon or ribavirin was 1.82. These
results suggest that if the patient used either peginterferon a-2a, pegin-
terferona-2b, or ribavirin, the depressive side effectswere likely to occur
1.82 times more when compared with other medications. Meanwhile,
coadministration of teprenone (GGA) with peginterferon or ribavirin
reducedROR to 1.13, indicating that teprenone (GGA) suppressed the de-
pressive side effects. We also observed gender differences in depression—
female cases with depression weremuch higher thanmale cases (Table 1).Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017Wecannot rule out limitations of our FAERS analysis and, in particular,
the reported drug side effects. Further experiments are needed for de-
pressive patients with or without teprenone.
In summary, we demonstrate for the first time the possibility of
using GGA to ameliorate depression via the HSP105-BDNF pathway.
These observations suggest that GGA-mediated HSP induction may
provide a novel therapeutic strategy for depression-like behavior.MATERIALS AND METHODS
All animal procedures were carried out in accordance with the Guide
for the Care and Use of Laboratory Animals published by the Japanese
Association for Laboratory Animal Science. All experiments were
approved by the Animal Care and Use Committee of the Okayama
University of Science. According to these guidelines, all efforts were
made to minimize the number of animals used and their discomfort.
Animals
Six-week-oldmale C57BL/6mice (not siblings, purchased from Shimizu
Experimental Animals) were housed in the Animal Research Center of
Okayama University of Science at a controlled ambient temperature of
22°C with 50 ± 10% relative humidity and a 12-hour light/dark cycle
(lights on at 7:00 a.m.). They were fed a normal chow diet and water ad
libitum for a 2-week habituation. All procedures were approved by the
institutional ethics committee (authorization numbers 20130205-1 and
2016-03).
Social defeat stress exposure
Social defeat stress was carried out using a previously reported method
(20). Testmice were exposed to a different CD1 strain aggressormouse
each day for 10 min for a total of 15 days. After 10 min of physical
contact, test mice were separated from the aggressor and placed across
a plastic separator with holes, where they remained in sensory contact
with the CD1 aggressor for the remainder of the 24 hours. Each day,
experimentalmicewere exposed to a new resident home cage. Controls
were housed individually. After the last defeat, a social interaction test
was performed to measure the behavioral consequences of the chronic
defeat stress.
GGA treatment
GGAand gum arabic were purchased fromWako Inc. For oral admin-
istration to mice, GGA granules were emulsified in 5% (v/v) gum ara-
bic at a concentration of 0.34% (w/v). The dosage of GGAwas selected
on the basis of the effective concentration response (800 mg/kg per
day) (31). Briefly, 8- to 10-week-old mice had an average body weight
of 25.5 g and an average daily water consumption of 6 ml, which was
why a concentration of 0.34% (w/v) was chosen. GGA was admini-
strated to mice from 8 weeks old until the end of the stress exposure.
The control and stressed mice group received drinking water supple-
mented with 5% (w/v) gum, which was used as a vehicle for GGA.
K252a (25 mg/kg, Sigma), a broad-spectrum tyrosine kinase antag-
onist, was used (35). To avoid any unwanted effects from K252a,
we intraperitoneally administered a low concentration of K252a (39)
15 days during the stress exposure.
Immunostaining
Brains were collected and immunostained, as previously described
(40). Briefly, mice were deeply anesthetized with sodium pentobarbital
(50mg/kg, intraperitoneally) and transcardially perfusedwith 0.9% (w/v)9 of 12









saline, followed by 4% (w/v) paraformaldehyde and 0.35% (v/v) glu-
taraldehyde in 0.1 M sodium phosphate buffer (PB) (pH 7.4). The
brains were postfixed overnight in 4% (w/v) paraformaldehyde in
0.1 M PB and cryoprotected in 15% (w/v) sucrose in 0.1 M PB with
0.1% (w/v) sodium azide overnight at 4°C. The brains were sectioned
(20 mm) using a cryostat, and immunohistochemistry was performed
on free-floating sections. Every 12th section was incubated with 2MHCl
in 0.1 M PB for 30 min at 65°C to block endogenous peroxidase.
Sections were then rinsed with 10 mM phosphate-buffered saline
(PBS; pH 7.4) and incubated for 1 hour in PBS containing 10% (v/v)
normal goat serum containing 1% (w/v) bovine serum albumin (BSA)
at room temperature. Thereafter, sections were incubated in a rabbit
anti-DCX antibody (1:1000; Abcam plc), rabbit anti-NeuN (1:1000,
Merck Millipore Co.), or rabbit anti-BDNF (1:300, Abcam) overnight
at 4°C. After washing, sections were incubated for 60min at room tem-
peraturewithAlexa Fluor 488 goat anti-rabbit immunoglobulinG (Life
Technologies) and diluted 1:400 in PBS containing 1% (w/v) BSA.
Following several washes in PBS, sections were coverslipped with glycerol/
PBS (1:1, v/v) and observed under a fluorescent microscope (EVOS
FLoid Cell Imaging Station, Life Technologies). All morphological
analyses were performed on blind-coded slides. The total number of
DCX- or NeuN-labeled cells in the dentate gyrus was counted for each
section. BDNF-positive cells were evaluated by density of area per
region using ImageJ (https://imagej.nih.gov/ij/). To evaluate neuro-
genesis, we examined DCX-positive cells in every 12th bilateral section
(240-mm interval). Cells throughout the granular zone were counted.
The number of DCX- or NeuN-positive cells was multiplied by a factor
of 12 to estimate the total number of each positive cell type.
Behavioral assessments
Open-field test
Spontaneous locomotor activity was evaluated using an open-field
test, as described previously (40). Mice were individually placed in
the center of a circle open-field chamber (diameter, 57.5 cm; height,
32 cm). All movements were recorded using a digital camera for
3 min. The floor was divided into 19 sections, with each section of ap-
proximately the same area. Briefly, two circles (13.5 and 35.5 cm in
diameter) were drawn, focusing on the center of the chamber. A line
was drawn radially and divided into 18 equal parts. Each section was
13.5 cm in diameter. The 35.5-cm-diameter circle was defined as the
center. Locomotor activity was scored when amouse removed all four
paws fromone section and entered another. The line crossings, rearing
(frequency with which the mice stood on their hind legs), and time
spent in the center were measured over the course of 3 min using a
counter or stopwatch. The apparatus was cleaned after each trial.
Social interaction test
Mice were placed in a new area (a 46 cm × 36 cm white plastic open
field) with a small-animal cage at one end and observed for 2.5 min
in the absence of another mouse, followed by 2.5 min in the presence
of a caged, unfamiliar target CD1 mouse. Social interaction was
quantified by stopwatch by comparing the amount of time that the
test mouse spent in the interaction zone near the small-animal cage
in the presence versus the absence of the target CD1 mouse.
Forced swim test
Animalswere placed in a 1-liter Griffin beaker [15 cm (height) × 11 cm
(diameter); filled with 28°C water to a depth of 10 cm] for 6 min, and
the duration of floating (that is, the time duringwhich the animalmade
only small movements necessary to keep its head above water) and the
latency to the immobility time were scored. Immobility time was ana-Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017lyzed during the last 5-min period of the test. The animals were then
dried and returned to their home cage.
Tail suspension test
The tail suspension test was performed on the basis of a previous
method (41). The mouse was hung 15 cm above the floor by the tip
of the tail (1 cm) and was adhered to an aluminum bar. The total test
procedure ofmouse immobility time was counted during a test period
of 6 min (1 min of adaptation time and 5 min of recording). A mouse
was considered immobile when it was passively suspended and com-
pletely motionless.
Sucrose preference test
The test was based onmethods describedbyUchida et al. (42). Animals
were habituated to drinkingwater from two bottles for 2 days following
the last defeat exposure. In the sucrose preference test, two preweighed
bottles [one containing tap water and the other containing a 1% (w/v)
sucrose solution] were presented to each animal for 4 hours. The
position of the water and sucrose bottles (left or right) was switched
every 2 hours. The bottles were weighed again, and the weight
difference represented the animal’s intake from each bottle. The sum
of water plus sucrose intake was defined as the total intake, and sucrose
preference was expressed as the percentage of sucrose intake relative to
the total intake.
RNA extraction
The animals were sacrificed on day 16 by administration of an
overdose of sodium pentobarbital (100 mg/kg). Total RNA was
extracted from the hippocampus, placed in RNAlater (Life Technolo-
gies), and stored at −30°C. Total RNAwas extracted using the RNeasy
Plus Micro Kit (Qiagen). At the end of the extraction, RNA samples
were dissolved in nuclease-free water (Qiagen), and the optical density
values of each sample were determined using an absorption meter
(Shimadzu Co.). We performed reverse transcription using Moloney
murine leukemia virus (Wako Pure Chemical Industries Ltd.)
according to the manufacturer’s protocol. Specificity of amplification
was verified by the monophasic characteristic of the melting curve
generated for each amplification product by the Eco Real-Time PCR
System (Illumina Inc.) at the end of a PCR.
Quantitative analysis by real-time PCR
The reverse-transcribed mixture was used as a template for subsequent
real-time PCR. Real-time PCR was performed according to the KAPA
SYBR Fast qPCR kit (Nippon Genetics Co. Ltd.) and analyzed with an
Eco Real-Time PCR System (Illumina Inc.). Primers, designed by the
authors, were based on the coding sequences of mouse genes deposited
inGenBank.Thedatawere analyzedwith themean threshold cycle equa-
tion. Primer information is shown in table S1. GAPDH served as an in-
ternal control. The threshold cycle values for both the target (HSPs or
neurotrophins) and internal control (GAPDH) genes were determined.
The fold change of each genewas normalized toGAPDHand, relative to
the expression in control samples, calculated for each sample.
Western blotting
ForWestern blot analysis, collected hippocampiwere placed in RNAlater
(Life Technologies) and homogenized in an SDS sample buffer. Protein
extracts were separated by SDS–polyacrylamide gel electrophoresis and
then transferred onto a polyvinylidene difluoride membrane (Hybond
P; GE Healthcare). The membrane was blocked with a blocking agent
(GE Healthcare) and then incubated at 4°C overnight with a primary
antibody for rabbit anti-HSP110 (1:5000, StressMarq Biosciences Inc.),10 of 12









rabbit anti-HSP25 (1:5000, Cosmo Bio Co. Ltd.), mouse anti-HSP60
(1:1000, Cosmo), mouse anti-HSP72 (1:1000, Cosmo), mouse anti–
phospho-CREB (Ser133) (1:5000, Cell Signaling Technology), rabbit
anti-CREB (Ser133) (1:5000, Cell Signaling), and rabbit anti-BDNF
(1:5000, Abcam). After washing with tris-buffered saline containing
0.1% (v/v) Tween 20, the membranes were incubated with horseradish
peroxidase–conjugated secondary antibody (1:20,000) for 1 hour at
room temperature. The antibody-reactive bands were visualized using
the chemiluminescent substrate kit (GE Healthcare). Bands were ana-
lyzed by densitometry using FluorChem 8800 (Alpha Innotech), and
the content ofGAPDH,whichwas detected using a rabbit anti-GAPDH
antibody (1:20,000; Sigma), was used as a control to ensure that the same
amount of protein was loaded in each lane.
siRNA constructs
The siRNA reagents used were Dharmacon Mouse ON-TARGET-
plus SMARTpool siRNA and Mouse ON-TARGETplus Non-targeting
siRNA (GE Healthcare Dharmacon Inc.).
Neuronal cell culture and transfection
The mouse hippocampal neuronal cell line HT22 was a gift from
H. Kimura (National Institute ofNeuroscience, Japan). HT22 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10%
(v/v) fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin
(100 mg/ml) at 37°C in a humidified atmosphere containing 5% (v/v)
CO2 and 95% air. The cells were seeded in 12-well plates at a density
of 0.2 × 105 cells per well. Twenty-four hours after being seeded, the
medium was replaced with antibiotic-free medium. HT22 cells were
transfectedusingLipofectamineRNAiMAXreagent (LifeTechnologies).
The siRNA-lipid complex (10 pmol) was added to cells and incubated
for 24 hours. The medium was changed 24 hours after transfection to
DMEM containing penicillin/streptomycin and 10% (v/v) FBS. Cells
were incubated with 50 mM GGA or vehicle [0.5% (v/v) ethanol–
containing medium] for 22 hours following heat shock at 41°C for
2 hours with 50 mM GGA or vehicle. GGA was dissolved in 100%
(v/v) ethanol. Following incubation, the cells were washed with PBS
buffer and lysed with RNAlater, and mRNA expression was evaluated
by real-time PCR.
Intracerebroventricular injection
Mice were divided into three groups: (i) vehicle [5% (v/v) gum arabic],
(ii) HSP105-siRNA intracerebroventricularly (ICV) with 0.34% (w/v)
GGA, (iii) and nontargeting control siRNA ICV with GGA on days 1,
7, and 14 during a 15-day stress exposure. Inhaled diethyl ether was
used for brief anesthesia during ICV injections. The siRNA transfec-
tions used in vivo-jetPEI reagent (Polyplus-transfection Inc.). siRNA-
polyethylenimine complex administration was performed by direct
injection into the right lateral ventricle through the intact scalp aiming
at 1 mm posterior to bregma and 1 mm right from the midline, as
described previously (40, 43).
FAERS data sources
Adverse events recorded from the third quarter of 2010 to the second
quarter of 2015 in the FAERS database were downloaded from the
FDA website (www.fda.gov). A total of 2,326,853 reports, which ex-
cluded reports with unknown age or gender, were obtained. The drug
selected for this investigation was teprenone (GGA pharmaceutical
drug name). We chose data where GGA was used as a concomitant
drug in patients aged 20 to 79 years. We investigated the effect of com-Hashikawa et al., Sci. Adv. 2017;3 : e1603014 31 May 2017bination treatment with GGA and interferons (peginterferon a-2a,
peginterferon a-2b, and ribavirin), which are well known as drugs
that induce depression (25, 26). All reported adverse events of interest
(depression, major depression, agitated depression, or depression sui-
cidal) were defined as “cases,” and all reported other adverse events
were defined as “non-cases.” The ROR was used as the signal score,
which was calculated using a case/non-case method (44, 45). A 2 × 2
contingency table was the framework for analysis (table S2). We
calculated signal scores to evaluate whether GGA was associated with
an adverse event.
Statistical analysis
All data are expressed as means ± SEM. GraphPad Prism 5 software
(GraphPad Software Inc.) was used for all statistical analyses.
Comparisons between two values were analyzed using one-tailed
Student’s t test. ANOVA followed by Tukey’s multiple comparison
test was used to determine statistical significance, where appropriate.
A P value of <0.05 was considered statistically significant. Two-way
ANOVAs were also performed: If a statistical interaction was observed
between factors, comparison of all four groups was performed by
Tukey’s post hoc test. Statistical differences are indicated by different
letters (P < 0.05). If no significant interaction was observed, statistical
effects of one or both factors are denoted as an inset for each group.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/5/e1603014/DC1
fig. S1. Effect of stress or GGA on mature neurons in the mouse hippocampus.
fig. S2. Effect of stress or GGA on BDNF distribution in the mouse hippocampus.
fig. S3. Effect of GGA or GGA + K252a on mouse behavior with nonstress conditioning.
fig. S4. Effect of HSP105-siRNA on expression of HSP25, HSP60, and HSP72 in the nonstressed
mouse hippocampus (n = 4 animals per group).
fig. S5. Effect of GGA on phospho-CREB expression in the stressedmouse hippocampus (stress +
VEH, n = 5; stress + GGA, n = 6 animals).
table S1. Oligonucleotide sequences for real-time PCR amplification.
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